Arctic Bioscience is pleased to invite investors, analysts, media and other stakeholders to a Capital Markets Update on 21 September 2022 in Oslo.
Presentations will be held by Arctic Bioscience management and external experts. The presentations and the following Q&A session will be held in Norwegian. The session will end with serving of a light lunch and mingling.
The event will take place at Flyt Conference Centre, Haakon VIIs gate 2 from 10.00 – 12.00 CEST
A recording of the event will be available on the company’s web site after the event.
To registrate your participance for the event, please send an email to Jone R. Slinning: email@example.com.
For further information, please contact
Christer L. Valderhaug, CEO
Mobile: +47 920 84 601
Jone R. Slinning, CFO
Mobile: +47 948 75 469
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 – a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a team of highly competent people with experience in developing marine oils and experience from global pharmaceutical companies.